Ronald Dullinger - 01 Jan 2026 Form 3 Insider Report for BIOCRYST PHARMACEUTICALS INC (BCRX)

Reporting relationship: Chief Commercial Officer
Issuer ticker: BCRX
Reported as of: 01 Jan 2026
Net transaction value: $0
SEC form: 3
Accepted by SEC: 09 Jan 2026, 19:19:54 UTC
Source filing: View source filing
Reporting owner signature: /s/ Alane P. Barnes, by power of attorney

Key filing fact

Ronald Dullinger filed Form 3 for BIOCRYST PHARMACEUTICALS INC (BCRX) on 09 Jan 2026.

Key facts

This page summarizes Ronald Dullinger's Form 3 filing for BIOCRYST PHARMACEUTICALS INC (BCRX).
0 reported transactions and 7 derivative rows are listed below.
Accepted by SEC: 09 Jan 2026, 19:19.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0002103871 Primary reporting owner

Dullinger Ronald

Relationship: Chief Commercial Officer
Address: 4505 EMPEROR BLVD, SUITE 200, DURHAM
Signature: /s/ Alane P. Barnes, by power of attorney
Signature date: 09 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BCRX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 258,372
Date: 01 Jan 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BCRX holding Derivative

Emp. Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 01 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 100,000
Exercise price: $2.85
Footnotes: F2

BCRX holding Derivative

Emp. Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 01 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 100,000
Exercise price: $8.31
Footnotes: F3

BCRX holding Derivative

Emp. Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 01 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 41,000
Exercise price: $11.43
Footnotes: F4

BCRX holding Derivative

Emp. Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 01 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 57,100
Exercise price: $10.63
Footnotes: F5

BCRX holding Derivative

Emp. Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 01 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 57,100
Exercise price: $6.43
Footnotes: F6

BCRX holding Derivative

Emp. Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 01 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 68,500
Exercise price: $7.39
Footnotes: F7

BCRX holding Derivative

Emp. Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 01 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 255,050
Exercise price: $7.13
Footnotes: F8

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 8 footnotes

Footnote F1

Includes 206,813 restricted stock units which vest 25% on each of the first, second, third and fourth anniversaries of the date of grant.

Footnote F2

Annual Employee Option Grant became exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. The option was granted on November 29, 2019.

Footnote F3

Annual Employee Option Grant became exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. The option was granted on December 15, 2020.

Footnote F4

Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. The option was granted on December 14, 2021.

Footnote F5

Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. The option was granted on December 19, 2022.

Footnote F6

Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. The option was granted on December 14, 2023.

Footnote F7

Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. The option was granted on December 19, 2024.

Footnote F8

Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. The option was granted on December 17, 2025.

SEC remarks

Exhibit List: Exhibit 24 - Power of Attorney

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .